3759 Stock Overview
Provides drug research and development, and production services to the life sciences industry in North America, Europe, Japan, Mainland China, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Pharmaron Beijing Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥13.08 |
| 52 Week High | CN¥24.85 |
| 52 Week Low | CN¥7.98 |
| Beta | 0.84 |
| 11 Month Change | -17.94% |
| 3 Month Change | 57.40% |
| 1 Year Change | -32.02% |
| 33 Year Change | -81.57% |
| 5 Year Change | n/a |
| Change since IPO | -81.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3759 | HK Life Sciences | HK Market | |
|---|---|---|---|
| 7D | -7.6% | -2.0% | -2.1% |
| 1Y | -32.0% | -58.9% | 9.7% |
Return vs Industry: 3759 exceeded the Hong Kong Life Sciences industry which returned -58.3% over the past year.
Return vs Market: 3759 underperformed the Hong Kong Market which returned 9.6% over the past year.
Price Volatility
| 3759 volatility | |
|---|---|
| 3759 Average Weekly Movement | 17.7% |
| Life Sciences Industry Average Movement | 12.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 19.1% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 3759's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 3759's weekly volatility has increased from 12% to 18% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 20,342 | Boliang Lou | www.pharmaron.com |
Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides drug research and development, and production services to the life sciences industry in North America, Europe, Japan, Mainland China, and internationally. The company offers laboratory chemistry services, including medicinal and synthetic chemistry, chemistry for new modalities, radiolabelling and radiosynthesis, analytical and purification chemistry, DNA-encoded libraries, cheminformatics, and computer-aided drug design; bioscience services, such as structural biology, in vitro biology, DMPK, in vivo pharmacology, and compound management services; chemistry, manufacturing, and controls services. It also provides clinical development services, including integrated radio labelled science, clinical development, and clinical trial recruitment services; safety assessment, integrated drug discovery, and bioanalysis services; and biologics and cell and gene therapy services, comprising biologics laboratory, biologics CDMO, cell and gene therapy laboratory, and gene therapy CDMO services.
Pharmaron Beijing Co., Ltd. Fundamentals Summary
| 3759 fundamental statistics | |
|---|---|
| Market cap | HK$46.68b |
| Earnings (TTM) | HK$2.02b |
| Revenue (TTM) | HK$12.67b |
25.4x
P/E Ratio4.1x
P/S RatioIs 3759 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3759 income statement (TTM) | |
|---|---|
| Revenue | CN¥11.80b |
| Cost of Revenue | CN¥7.77b |
| Gross Profit | CN¥4.02b |
| Other Expenses | CN¥2.14b |
| Earnings | CN¥1.88b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.06 |
| Gross Margin | 34.12% |
| Net Profit Margin | 15.97% |
| Debt/Equity Ratio | 38.7% |
How did 3759 perform over the long term?
See historical performance and comparison